U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H28ClNO
Molecular Weight 357.917
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SETASTINE

SMILES

CC(OCCN1CCCCCC1)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=VBSPHZOBAOWFCL-UHFFFAOYSA-N
InChI=1S/C22H28ClNO/c1-22(19-9-5-4-6-10-19,20-11-13-21(23)14-12-20)25-18-17-24-15-7-2-3-8-16-24/h4-6,9-14H,2-3,7-8,15-18H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H28ClNO
Molecular Weight 357.917
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Setastine (Loderix) is a potent antagonist of histamine H1-receptor mediated responses. Setastine inhibits anaphylactic shock in guinea-pigs sensitized by horse serum. No antiserotonin, anticholinergic and antiadrenergic effect of the compound can be detected. Setastine has a long lasting (up to 16 h) antihistamine effect with a good oral effectiveness. It shows no cardiovascular effects in cats. Setastine shows a much weaker CNS depressant activity than clemestine fumarate. In displacement studies (3H-mepyramine) setastine had significantly weaker affinity for the central nervous system (CNS) H1-receptors than clemastine fumarate. It is concluded that setastine is a non-sedative highly active H1-antagonist.

CNS Activity

Curator's Comment: Setastine shows a much weaker CNS depressant activity than clemestine fumarate. In displacement studies (3H-mepyramine) setastine had significantly weaker affinity for the central nervous system (CNS) H1-receptors than clemastine fumarate. It is concluded that setastine is a non-sedative highly active H1-antagonist.

Originator

Curator's Comment: Setastine as a new generation of allergy medications first successfully developed by Hungarian company Egis Pharmaceuticals Ltd and first marketed in Hungary in 1987.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

For prolonged use a dose of 2 mg three times/day (t.i.d.) is recommended. The antihistaminic effect of setastine almost equalled that of clemastine given in a dose of 1 mg t.i.d.
Route of Administration: Oral
In Vitro Use Guide
At low concentrations Setastine (Loderix) preincubated with rat peritoneal mast cells for 10 min prior to the addition of various stimulants (immune aggregates, ionophore A23187 and compound 48/80) produced a concentration-dependent inhibition of histamine release, while at high concentrations it induced the release of histamine. The IC50 values were calculated as 0.2, 15 and 50 uM by using immune aggregate, (rat IgG2 alpha + anti rat IgG) calcium ionophore and 48/80 as stimulants, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:27:31 GMT 2023
Edited
by admin
on Fri Dec 15 16:27:31 GMT 2023
Record UNII
6G3OCF528J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SETASTINE
INN   MI   WHO-DD  
INN  
Official Name English
SETASTINE [MI]
Common Name English
setastine [INN]
Common Name English
Setastine [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
Code System Code Type Description
FDA UNII
6G3OCF528J
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
NCI_THESAURUS
C73056
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
DRUG CENTRAL
2437
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
MERCK INDEX
m9881
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY Merck Index
CAS
64294-95-7
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID30867067
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
SMS_ID
100000084341
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
INN
4447
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
PUBCHEM
43082
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
MESH
C053758
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
EVMPD
SUB10500MIG
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
ChEMBL
CHEMBL1742452
Created by admin on Fri Dec 15 16:27:31 GMT 2023 , Edited by admin on Fri Dec 15 16:27:31 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY